| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2024-05-08 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-05-08 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-26 | Karolinska Development AB (publ) | Interim Report - January-March 2024 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-26 | Karolinska Development AB (publ) | Delårsrapport för januari – mars 2024 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-16 | Karolinska Development AB (publ) | Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-16 | Karolinska Development AB (publ) | Notice of Annual General Meeting in Karolinska Development AB (publ) | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-22 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-22 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC | Pressreleaser | Visa Stäng |
|
Pressreleaser |
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBCSTOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented a positive safety data from the first part of its clinical Phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. The second part of the study, which will now be initiated, aims to evaluate the preliminary efficacy of the drug candidate and further study its safety and tolerability profile. Top-line results are expected in H1, 2025. Umecrine Cognition is developing a new class of drugs to treat cognitive symptoms caused by liver disease. The company’s lead drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled, clinical Phase 1b/2 study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. The first part of the study aimed to evaluate golexanolone’s safety and tolerability profile, as well as the pharmacokinetic profile, and the data generated provided important guidance on the dosing intervals in the second part of the study. The study’s internal safety review committee (iSRC) has authorized the initiation of the second part of the study without dose adjustments and the first patient is expected to be included during the second quarter. Approximately 84 subjects will be randomized to the second part of the study which aims to investigate preliminary treatment efficacy signals. The evaluation also includes a planned interim analysis when a third of the patients have been included. Top-line results are expected in H1, 2025. ”In previous clinical and preclinical studies, Umecrine Cognition’s drug candidate golexanolone has shown strong potential to counteract an incorrect suppression of brain activity, causing extreme fatigue and difficulty with concentration. We are happy that the current study is progressing and look forward to the results from the second part,” says Viktor Drvota, CEO of Karolinska Development. Karolinska Development’s ownership in Umecrine Cognition amounts to 73 percent. For further information, please contact : Viktor Drvota, CEO, Karolinska Development AB Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit www.karolinskadevelopment.com . Attachment
|
||||
| 2024-03-22 | Karolinska Development AB (publ) | Karolinska Development Annual Report 2023 published | Rapporter | Visa Stäng |
|
|
||||
| 2024-03-22 | Karolinska Development AB (publ) | Karolinska Developments årsredovisning för 2023 har publicerats | Rapporter | Visa Stäng |
|
|
||||
| 2024-03-14 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-14 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Aprea Therapeutics får IND-godkännande från FDA och säkrar finansiering om USD 34 miljoner | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-14 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-14 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Biosergen publicerar prospekt i samband med emission av units | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-06 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar prekliniska Parkinsondata för golexanolon på AD/PD | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-06 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: Karolinska Development - Kraftig substansrabatt | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-16 | Karolinska Development AB (publ) | Bokslutskommuniké för januari – december 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-16 | Karolinska Development AB (publ) | Year-end Report - January-December 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-01-17 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-01-17 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag AnaCardio säkrar 50 MSEK inom ramarna för sin serie A-finansieringsrunda | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-01-09 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign rapporterar exceptionella kliniska data för sitt nanosyntetiska bengraft | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-01-09 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-06 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-06 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-04 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovos läkemedelskandidat PN6047 i NIDA-finansierat samarbete | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-04 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-28 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-28 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-21 | Penser Access | Penser Access: Ett kvartal utan överraskningar - Karolinska Development | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-17 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-17 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition säkrar ytterligare finansiering för den kliniska utvecklingen av golexanolon | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-17 | Karolinska Development AB (publ) | Delårsrapport för januari – september 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-17 | Karolinska Development AB (publ) | Interim Report - January-September 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Karolinska Development AB (publ) | Karolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Modus Therapeutics genomför kapitalanskaffning inför breddning av utvecklingsprogrammet för sevuparin | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-10-02 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-10-02 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovo presenterar positiva data från klinisk fas 1-studie med läkemedelskandidaten PN6047 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-28 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-28 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovo presenterar lovande resultat från en preklinisk studie som visar att inga beroendeframkallande effekter finns samt att lindrande av abstinenssymtom med läkemedelskandidaten PN6047 föreligger | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-27 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign tar in SEK 150 miljoner och renodlar sin verksamhet för fullt fokus på ortobiologimarknaden | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-27 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-19 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-19 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign får utökat marknadsgodkännande från FDA för ny betydande indikation | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-28 | Penser Access | Penser Access: Medvind i de noterade innehaven - Karolinska Development | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-25 | Karolinska Development AB (publ) | Interim Report - January-June 2023 | Rapporter | Visa Stäng |
|
|
||||
| 2023-08-25 | Karolinska Development AB (publ) | Delårsrapport för januari – juni 2023 | Rapporter | Visa Stäng |
|
|
||||
| 2023-07-05 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar resultat från studie av golexanolon i en preklinisk modell av Parkinsons sjukdom | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-07-05 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-06-07 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar data som visar golexanolons verkningsmekanism och förmåga att minska neuroinflammation | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-06-07 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-05-16 | Karolinska Development AB (publ) | Karolinska Developments årsstämma 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-05-16 | Karolinska Development AB (publ) | Karolinska Development’s Annual General Meeting 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-05-12 | Karolinska Development AB (publ) | Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-05-12 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Modus Therapeutics ser potential för sin läkemedelskandidat sevuparin inom behandling av anemi | Pressreleaser | Visa Stäng |
|
|
||||
Kommande händelser
